{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:28:29Z","timestamp":1793316509683,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA142543"],"award-info":[{"award-number":["5P30CA142543"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["Lung Cancer SPORE Development Research Program"],"award-info":[{"award-number":["Lung Cancer SPORE Development Research Program"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA248736"],"award-info":[{"award-number":["R01CA248736"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA263079"],"award-info":[{"award-number":["R01CA263079"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220032"],"award-info":[{"award-number":["RP220032"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP15150551"],"award-info":[{"award-number":["RP15150551"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP190561"],"award-info":[{"award-number":["RP190561"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["AU-0042-20030616"],"award-info":[{"award-number":["AU-0042-20030616"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Amyloid proteins are linked to various diseases; however, their functional roles in immunity and cancer remain unclear. Here, we establish a direct link between oligomeric cystatin C\u2014a cysteine cathepsin inhibitor and a well-characterized amyloidogenic protein\u2014within the tumor microenvironment and the immune inhibitory receptors LILRB2 and LILRB5 on myeloid cells. We demonstrated that human LILRB2 and LILRB5, along with their murine counterpart PIRB, serve as functional receptors for cystatin C oligomers. Engagement of these inhibitory receptors by oligomeric cystatin C enhances the immunosuppressive activity of myeloid cells, leading to T-cell suppression and tumor progression. Deletion of the\n                    <jats:italic>CST3<\/jats:italic>\n                    gene, which encodes cystatin C, in host mice and tumor cells impaired tumor growth, whereas its overexpression accelerated cancer progression in LILRB2 and LILRB5 transgenic mice. Mechanistically, cystatin C\u2013LILRB2 signaling is driven by both canonical phosphatases and the enhanced TGF-\u03b2 pathway. Additionally, we identified interactions between LILRB receptors and transthyretin oligomers, another amyloid linked to transthyretin amyloidosis, suggesting a broader paradigm of amyloid\u2013LILRB interactions. Our findings reveal an unexpected role of oligomeric cystatin C in enhancing myeloid cell immunosuppression, expand the functional spectrum of amyloid proteins and underscore the importance of these proteins in immune evasion and cancer development.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02462-x","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T23:03:15Z","timestamp":1763074995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors"],"prefix":"10.1038","volume":"10","author":[{"given":"Chengcheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bufan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc I.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-2335","authenticated-orcid":false,"given":"Zhiqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-3887","authenticated-orcid":false,"given":"Cheng Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2462_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","volume":"86","author":"F Chiti","year":"2017","unstructured":"Chiti, F. & Dobson, C. M. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu. Rev. Biochem. 86, 27\u201368 (2017).","journal-title":"Annu. Rev. Biochem."},{"key":"2462_CR2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2174\/1871527313666140806124850","volume":"13","author":"ME Gambuzza","year":"2014","unstructured":"Gambuzza, M. E. et al. Toll-like receptors in Alzheimer\u2019s disease: a therapeutic perspective. CNS Neurol. Disord. Drug Targets 13, 1542\u20131558 (2014).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"2462_CR3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1126\/science.1242077","volume":"341","author":"T Kim","year":"2013","unstructured":"Kim, T. et al. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer\u2019s model. Science 341, 1399\u20131404 (2013).","journal-title":"Science"},{"key":"2462_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-928","volume":"14","author":"S Lim","year":"2014","unstructured":"Lim, S. et al. Amyloid-beta precursor protein promotes cell proliferation and motility of advanced breast cancer. BMC Cancer 14, 928 (2014).","journal-title":"BMC Cancer"},{"key":"2462_CR5","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.21037\/tcr-20-3417","volume":"10","author":"Y Lai","year":"2021","unstructured":"Lai, Y., Li, Y. & Gao, L. Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review. Transl. Cancer Res. 10, 2255\u20132264 (2021).","journal-title":"Transl. Cancer Res."},{"key":"2462_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06424-z","volume":"15","author":"F Farris","year":"2024","unstructured":"Farris, F. et al. Unveiling the mechanistic link between extracellular amyloid fibrils, mechano-signaling and YAP activation in cancer. Cell Death. Dis. 15, 28 (2024).","journal-title":"Cell Death. Dis."},{"key":"2462_CR7","doi-asserted-by":"publisher","first-page":"e2300070","DOI":"10.1002\/adbi.202300070","volume":"7","author":"Y Tang","year":"2023","unstructured":"Tang, Y., Zhang, D., Robinson, S. & Zheng, J. Inhibition of pancreatic cancer cells by different amyloid proteins reveals an inverse relationship between neurodegenerative diseases and cancer. Adv. Biol. 7, e2300070 (2023).","journal-title":"Adv. Biol."},{"key":"2462_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0140-6736(88)90641-1","volume":"2","author":"A Palsdottir","year":"1988","unstructured":"Palsdottir, A. et al. Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet 2, 603\u2013604 (1988).","journal-title":"Lancet"},{"key":"2462_CR9","doi-asserted-by":"publisher","first-page":"100347","DOI":"10.1016\/j.xgen.2023.100347","volume":"3","author":"SO Kleeman","year":"2023","unstructured":"Kleeman, S. O. et al. Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapye. Cell Genom. 3, 100347 (2023).","journal-title":"Cell Genom."},{"key":"2462_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24722-4","volume":"12","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Association of plasma cystatin C with all-cause and cause-specific mortality among middle-aged and elderly individuals: a prospective community-based cohort study. Sci. Rep. 12, 22265 (2022).","journal-title":"Sci. Rep."},{"key":"2462_CR11","doi-asserted-by":"publisher","first-page":"e2204177","DOI":"10.1002\/advs.202204177","volume":"10","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Cancer cells enter an adaptive persistence to survive radiotherapy and repopulate tumor. Adv. Sci. 10, e2204177 (2023).","journal-title":"Adv. Sci."},{"key":"2462_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.lfs.2018.04.013","volume":"202","author":"G Leto","year":"2018","unstructured":"Leto, G., Crescimanno, M. & Flandina, C. On the role of Cystatin C in cancer progression. Life Sci. 202, 152\u2013160 (2018).","journal-title":"Life Sci."},{"key":"2462_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","volume":"23","author":"ST Barry","year":"2023","unstructured":"Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D. & Morton, J. P. Therapeutic targeting of tumour myeloid cells. Nat. Rev. Cancer 23, 216\u2013237 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2462_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1286-4579(00)00294-X","volume":"2","author":"J Dietrich","year":"2000","unstructured":"Dietrich, J., Nakajima, H. & Colonna, M. Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells. Microbes Infect. 2, 323\u2013329 (2000).","journal-title":"Microbes Infect."},{"key":"2462_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/jhg.2015.64","volume":"60","author":"K Hirayasu","year":"2015","unstructured":"Hirayasu, K. & Arase, H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J. Hum. Genet. 60, 703\u2013708 (2015).","journal-title":"J. Hum. Genet."},{"key":"2462_CR16","first-page":"275302","volume":"2011","author":"T Takai","year":"2011","unstructured":"Takai, T., Nakamura, A. & Endo, S. Role of PIR-B in autoimmune glomerulonephritis. J. Biomed. Biotechnol. 2011, 275302 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"2462_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-017-2023-x","volume":"66","author":"W van der Touw","year":"2017","unstructured":"van der Touw, W., Chen, H. M., Pan, P. Y. & Chen, S. H. LILRB receptor-mediated regulation of myeloid cell maturation and function. Cancer Immunol. Immunother. 66, 1079\u20131087 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"2462_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3389\/fimmu.2020.00857","volume":"11","author":"AL Lewis Marffy","year":"2020","unstructured":"Lewis Marffy, A. L. & McCarthy, A. J. Leukocyte Immunoglobulin-Like receptors (LILRs) on human neutrophils: modulators of infection and immunity. Front. Immunol. 11, 857 (2020).","journal-title":"Front. Immunol."},{"key":"2462_CR19","doi-asserted-by":"publisher","first-page":"1282874","DOI":"10.3389\/fimmu.2023.1282874","volume":"14","author":"S Redondo-Garcia","year":"2023","unstructured":"Redondo-Garcia, S. et al. Human leukocyte immunoglobulin-like receptors in health and disease. Front. Immunol. 14, 1282874 (2023).","journal-title":"Front. Immunol."},{"key":"2462_CR20","first-page":"16","volume":"4","author":"M Deng","year":"2021","unstructured":"Deng, M. et al. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Antib. Ther. 4, 16\u201333 (2021).","journal-title":"Antib. Ther."},{"key":"2462_CR21","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1073\/pnas.94.10.5261","volume":"94","author":"H Kubagawa","year":"1997","unstructured":"Kubagawa, H., Burrows, P. D. & Cooper, M. D. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc. Natl. Acad. Sci. USA 94, 5261\u20135266 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2462_CR22","doi-asserted-by":"publisher","first-page":"10809","DOI":"10.1073\/pnas.93.20.10809","volume":"93","author":"HR Katz","year":"1996","unstructured":"Katz, H. R. et al. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high-affinity Fc receptor for IgE. Proc. Natl. Acad. Sci. USA 93, 10809\u201310814 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2462_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng, M. et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562, 605\u2013609 (2018).","journal-title":"Nature"},{"key":"2462_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature11095","volume":"485","author":"J Zheng","year":"2012","unstructured":"Zheng, J. et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature 485, 656\u2013660 (2012).","journal-title":"Nature"},{"key":"2462_CR25","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/s43018-021-00262-0","volume":"2","author":"G Wu","year":"2021","unstructured":"Wu, G. et al. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-kappaB signaling axis. Nat. Cancer 2, 1170\u20131184 (2021).","journal-title":"Nat. Cancer"},{"key":"2462_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal, A. A. et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 19, 76\u201384 (2018).","journal-title":"Nat. Immunol."},{"key":"2462_CR27","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1172\/JCI97570","volume":"128","author":"H Chen","year":"2018","unstructured":"Chen, H. et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J. Clin. Invest. 128, 5647\u20135662 (2018).","journal-title":"J. Clin. Invest."},{"key":"2462_CR28","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John, S. et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol. Ther. 26, 2487\u20132495 (2018).","journal-title":"Mol. Ther."},{"key":"2462_CR29","doi-asserted-by":"publisher","first-page":"e000515","DOI":"10.1136\/jitc-2019-000515","volume":"8","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. J. Immunother. Cancer 8, e000515 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2462_CR30","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1158\/1535-7163.MCT-20-0407","volume":"19","author":"Y Anami","year":"2020","unstructured":"Anami, Y. et al. LILRB4-targeting Antibody-Drug conjugates for the treatment of acute myeloid leukemia. Mol. Cancer Ther. 19, 2330\u20132339 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2462_CR31","doi-asserted-by":"publisher","first-page":"996026","DOI":"10.3389\/fimmu.2022.996026","volume":"13","author":"J Xie","year":"2022","unstructured":"Xie, J. et al. Blocking LAIR1 signaling in immune cells inhibits tumor development. Front. Immunol. 13, 996026 (2022).","journal-title":"Front. Immunol."},{"key":"2462_CR32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/2326-6066.CIR-23-0496","volume":"12","author":"R Huang","year":"2024","unstructured":"Huang, R. et al. LILRB3 supports immunosuppressive activity of myeloid cells and tumor development. Cancer Immunol. Res. 12, 350\u2013362 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"2462_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/2326-6066.CIR-24-0737","volume":"13","author":"Y He","year":"2025","unstructured":"He, Y. et al. Eph receptors activate myeloid checkpoint receptor LILRB5 to support tumor development. Cancer Immunol. Res. 13, 821\u2013835 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"2462_CR34","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41590-025-02233-4","volume":"26","author":"X Yang","year":"2025","unstructured":"Yang, X. et al. Secretogranin 2 binds LILRB4 resulting in immunosuppression. Nat. Immunol. 26, 1567\u20131580 (2025).","journal-title":"Nat. Immunol."},{"key":"2462_CR35","doi-asserted-by":"publisher","first-page":"e20201811","DOI":"10.1084\/jem.20201811","volume":"218","author":"N Sharma","year":"2021","unstructured":"Sharma, N., Atolagbe, O. T., Ge, Z. & Allison, J. P. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J. Exp. Med. 218, e20201811 (2021).","journal-title":"J. Exp. Med."},{"key":"2462_CR36","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1158\/2326-6066.CIR-21-0240","volume":"9","author":"KJ Paavola","year":"2021","unstructured":"Paavola, K. J. et al. The Fibronectin-ILT3 interaction functions as a stromal checkpoint that suppresses myeloid cells. Cancer Immunol. Res. 9, 1283\u20131297 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"2462_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/1541-7786.MCR-20-0622","volume":"19","author":"L Singh","year":"2021","unstructured":"Singh, L. et al. ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells. Mol. Cancer Res. 19, 702\u2013716 (2021).","journal-title":"Mol. Cancer Res."},{"key":"2462_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/86188","volume":"8","author":"R Janowski","year":"2001","unstructured":"Janowski, R. et al. Human Cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat. Struct. Biol. 8, 316\u2013320 (2001).","journal-title":"Nat. Struct. Biol."},{"key":"2462_CR39","doi-asserted-by":"publisher","first-page":"e18262","DOI":"10.1111\/jcmm.18262","volume":"28","author":"X Zhang","year":"2024","unstructured":"Zhang, X., Xiao, Q., Zhang, C., Zhou, Q. & Xu, T. Construction of a prognostic model with CAFs for predicting the prognosis and immunotherapeutic response of lung squamous cell carcinoma. J. Cell. Mol. Med. 28, e18262 (2024).","journal-title":"J. Cell. Mol. Med."},{"key":"2462_CR40","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/2159-8290.CD-12-0527","volume":"3","author":"Y Pang","year":"2013","unstructured":"Pang, Y. et al. TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 3, 936\u2013951 (2013).","journal-title":"Cancer Discov."},{"key":"2462_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2007.12.004","volume":"13","author":"L Yang","year":"2008","unstructured":"Yang, L. et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23\u201335 (2008).","journal-title":"Cancer Cell"},{"key":"2462_CR42","doi-asserted-by":"publisher","first-page":"e1003251","DOI":"10.1371\/journal.pgen.1003251","volume":"9","author":"BR Achyut","year":"2013","unstructured":"Achyut, B. R. et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. PLoS Genet 9, e1003251 (2013).","journal-title":"PLoS Genet"},{"key":"2462_CR43","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nature04846","volume":"441","author":"B Kim","year":"2006","unstructured":"Kim, B. et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441, 1015\u20131019 (2006).","journal-title":"Nature"},{"key":"2462_CR44","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.1090922","volume":"303","author":"NA Bhowmick","year":"2004","unstructured":"Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848\u2013851 (2004).","journal-title":"Science"},{"key":"2462_CR45","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/0092-8674(92)90395-S","volume":"71","author":"JL Wrana","year":"1992","unstructured":"Wrana, J. L. et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71, 1003\u20131014 (1992).","journal-title":"Cell"},{"key":"2462_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature02006","volume":"425","author":"R Derynck","year":"2003","unstructured":"Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577\u2013584 (2003).","journal-title":"Nature"},{"key":"2462_CR47","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/ncb1780","volume":"10","author":"A Sorrentino","year":"2008","unstructured":"Sorrentino, A. et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10, 1199\u20131207 (2008).","journal-title":"Nat. Cell Biol."},{"key":"2462_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.molcel.2007.11.039","volume":"29","author":"J Groppe","year":"2008","unstructured":"Groppe, J. et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 29, 157\u2013168 (2008).","journal-title":"Mol. Cell"},{"key":"2462_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1541-7786.183.2.3","volume":"2","author":"JP Sokol","year":"2004","unstructured":"Sokol, J. P. & Schiemann, W. P. Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol. Cancer Res. 2, 183\u2013195 (2004).","journal-title":"Mol. Cancer Res."},{"key":"2462_CR50","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1126\/science.1079469","volume":"300","author":"R Kayed","year":"2003","unstructured":"Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486\u2013489 (2003).","journal-title":"Science"},{"key":"2462_CR51","doi-asserted-by":"publisher","first-page":"27207","DOI":"10.1074\/jbc.M101024200","volume":"276","author":"A Quintas","year":"2001","unstructured":"Quintas, A., Vaz, D. C., Cardoso, I., Saraiva, M. J. & Brito, R. M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 276, 27207\u201327213 (2001).","journal-title":"J. Biol. Chem."},{"key":"2462_CR52","doi-asserted-by":"publisher","first-page":"105313","DOI":"10.1016\/j.neuint.2022.105313","volume":"155","author":"M Ueda","year":"2022","unstructured":"Ueda, M. Transthyretin: Its function and amyloid formation. Neurochem. Int. 155, 105313 (2022).","journal-title":"Neurochem. Int."},{"key":"2462_CR53","doi-asserted-by":"publisher","first-page":"11442","DOI":"10.1021\/bi011194d","volume":"40","author":"X Jiang","year":"2001","unstructured":"Jiang, X. et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40, 11442\u201311452 (2001).","journal-title":"Biochemistry"},{"key":"2462_CR54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/(SICI)1098-1004(1997)9:3<226::AID-HUMU3>3.0.CO;2-5","volume":"9","author":"IL Alves","year":"1997","unstructured":"Alves, I. L., Altland, K., Almeida, M. R., Winter, P. & Saraiva, M. J. Screening and biochemical characterization of transthyretin variants in the Portuguese population. Hum. Mutat. 9, 226\u2013233 (1997).","journal-title":"Hum. Mutat."},{"key":"2462_CR55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrd3675","volume":"11","author":"G Said","year":"2012","unstructured":"Said, G., Grippon, S. & Kirkpatrick, P. Tafamidis. Nat. Rev. Drug Discov. 11, 185\u2013186 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2462_CR56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bbrc.2022.09.019","volume":"633","author":"CC Zhang","year":"2022","unstructured":"Zhang, C. C. A perspective on LILRBs and LAIR1 as immune checkpoint targets for cancer treatment. Biochem. Biophys. Res. Commun. 633, 64\u201367 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2462_CR57","doi-asserted-by":"publisher","first-page":"jcs261001","DOI":"10.1242\/jcs.261001","volume":"136","author":"S Noshita","year":"2023","unstructured":"Noshita, S. et al. A TGF-beta-responsive enhancer regulates SRC expression and epithelial-mesenchymal transition-associated cell migration. J. Cell Sci. 136, jcs261001 (2023).","journal-title":"J. Cell Sci."},{"key":"2462_CR58","doi-asserted-by":"publisher","first-page":"eabp9521","DOI":"10.1126\/scisignal.abp9521","volume":"15","author":"I Yakymovych","year":"2022","unstructured":"Yakymovych, I., Yakymovych, M., Hamidi, A., Landstrom, M. & Heldin, C. H. The type II TGF-beta receptor phosphorylates Tyr(182) in the type I receptor to activate downstream Src signaling. Sci. Signal. 15, eabp9521 (2022).","journal-title":"Sci. Signal."},{"key":"2462_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1006\/jmbi.1997.1150","volume":"271","author":"I Ekiel","year":"1997","unstructured":"Ekiel, I. et al. NMR structural studies of human cystatin C dimers and monomers. J. Mol. Biol. 271, 266\u2013277 (1997).","journal-title":"J. Mol. Biol."},{"key":"2462_CR60","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.0.CO;2-M","volume":"83","author":"S Coulibaly","year":"1999","unstructured":"Coulibaly, S. et al. Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int. J. Cancer 83, 526\u2013531 (1999).","journal-title":"Int. J. Cancer"},{"key":"2462_CR61","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/mp.52.6.332","volume":"52","author":"CG Huh","year":"1999","unstructured":"Huh, C. G. et al. Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol. Pathol. 52, 332\u2013340 (1999).","journal-title":"Mol. Pathol."},{"key":"2462_CR62","doi-asserted-by":"publisher","first-page":"73793","DOI":"10.18632\/oncotarget.17379","volume":"8","author":"J Zavrsnik","year":"2017","unstructured":"Zavrsnik, J. et al. Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells. Oncotarget 8, 73793\u201373809 (2017).","journal-title":"Oncotarget"},{"key":"2462_CR63","first-page":"505","volume":"6","author":"J Kos","year":"2000","unstructured":"Kos, J. et al. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin. Cancer Res. 6, 505\u2013511 (2000).","journal-title":"Clin. Cancer Res."},{"key":"2462_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22479-4","volume":"12","author":"K Kim","year":"2021","unstructured":"Kim, K. et al. Therapeutic B-cell depletion reverses progression of Alzheimer\u2019s disease. Nat. Commun. 12, 2185 (2021).","journal-title":"Nat. Commun."},{"key":"2462_CR65","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41591-018-0309-y","volume":"25","author":"Y Gu","year":"2019","unstructured":"Gu, Y. et al. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nat. Med. 25, 312\u2013322 (2019).","journal-title":"Nat. Med."},{"key":"2462_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44811-1","volume":"9","author":"M Taube","year":"2019","unstructured":"Taube, M. et al. The domain swapping of human cystatin C induced by synchrotron radiation. Sci. Rep. 9, 8548 (2019).","journal-title":"Sci. Rep."},{"key":"2462_CR67","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-019-1019-4","volume":"567","author":"MMS Obradovic","year":"2019","unstructured":"Obradovic, M. M. S. et al. Glucocorticoids promote breast cancer metastasis. Nature 567, 540\u2013544 (2019).","journal-title":"Nature"},{"key":"2462_CR68","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1074\/jbc.271.3.1314","volume":"271","author":"I Ekiel","year":"1996","unstructured":"Ekiel, I. & Abrahamson, M. Folding-related dimerization of human cystatin C. J. Biol. Chem. 271, 1314\u20131321 (1996).","journal-title":"J. Biol. Chem."},{"key":"2462_CR69","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/07391102.2007.10507162","volume":"25","author":"H Liu","year":"2007","unstructured":"Liu, H. et al. Molecular dynamics simulations of human cystatin C and its L68Q varient to investigate the domain swapping mechanism. J. Biomol. Struct. Dyn. 25, 135\u2013144 (2007).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"2462_CR70","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C. & Gage, F. H. Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918\u2013934 (2010).","journal-title":"Cell"},{"key":"2462_CR71","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.expneurol.2014.04.030","volume":"257","author":"NP Goncalves","year":"2014","unstructured":"Goncalves, N. P., Teixeira-Coelho, M. & Saraiva, M. J. The inflammatory response to sciatic nerve injury in a familial amyloidotic polyneuropathy mouse model. Exp. Neurol. 257, 76\u201387 (2014).","journal-title":"Exp. Neurol."},{"key":"2462_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1369-4","volume":"19","author":"EP Azevedo","year":"2019","unstructured":"Azevedo, E. P. et al. Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurol. 19, 146 (2019).","journal-title":"BMC Neurol."},{"key":"2462_CR73","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","volume":"21","author":"MM Sousa","year":"2001","unstructured":"Sousa, M. M. et al. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 21, 7576\u20137586 (2001).","journal-title":"J. Neurosci."},{"key":"2462_CR74","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/76216","volume":"6","author":"SD Yan","year":"2000","unstructured":"Yan, S. D. et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6, 643\u2013651 (2000).","journal-title":"Nat. Med."},{"key":"2462_CR75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/archneurol.2010.1","volume":"67","author":"JM Bertoni","year":"2010","unstructured":"Bertoni, J. M. et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch. Neurol. 67, 347\u2013352 (2010).","journal-title":"Arch. Neurol."},{"key":"2462_CR76","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/jnnp-2014-310239","volume":"87","author":"U Walter","year":"2016","unstructured":"Walter, U. et al. Frequency and profile of Parkinson\u2019s disease prodromi in patients with malignant melanoma. J. Neurol. Neurosurg. Psychiatry 87, 302\u2013310 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2462_CR77","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/2159-8290.CD-21-1006","volume":"12","author":"K Kleffman","year":"2022","unstructured":"Kleffman, K. et al. Melanoma-secreted amyloid beta suppresses neuroinflammation and promotes brain metastasis. Cancer Discov. 12, 1314\u20131335 (2022).","journal-title":"Cancer Discov."},{"key":"2462_CR78","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4065\/mcp.2009.0547","volume":"85","author":"S Madan","year":"2010","unstructured":"Madan, S. et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin. Proc. 85, 232\u2013238 (2010).","journal-title":"Mayo Clin. Proc."},{"key":"2462_CR79","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3332\/ecancer.2020.1156","volume":"14","author":"MA Algarra","year":"2020","unstructured":"Algarra, M. A. et al. Advanced systemic amyloidosis secondary to metastatic renal cell carcinoma. Ecancermedicalscience 14, 1156 (2020).","journal-title":"Ecancermedicalscience"},{"key":"2462_CR80","first-page":"361","volume":"19","author":"ARA Amir","year":"2006","unstructured":"Amir, A. R. A. & Sheikh, S. S. Hodgkin\u2019s lymphoma with concurrent systemic amyloidosis, presenting as acute renal failure, following lymphomatoid papulosis. J. Nephrol. 19, 361\u2013365 (2006).","journal-title":"J. Nephrol."},{"key":"2462_CR81","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2020.00532","volume":"11","author":"M Ohms","year":"2020","unstructured":"Ohms, M., Moller, S. & Laskay, T. An attempt to polarize human neutrophils toward N1 and N2 phenotypes in vitro. Front. Immunol. 11, 532 (2020).","journal-title":"Front. Immunol."},{"key":"2462_CR82","doi-asserted-by":"publisher","first-page":"eabb1069","DOI":"10.1126\/scitranslmed.abb1069","volume":"13","author":"Y Fan","year":"2021","unstructured":"Fan, Y. et al. Targeting multiple cell death pathways extends the shelf life and preserves the function of human and mouse neutrophils for transfusion. Sci. Transl. Med. 13, eabb1069 (2021).","journal-title":"Sci. Transl. Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02462-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02462-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02462-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T23:03:17Z","timestamp":1763074997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02462-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2462"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02462-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.Z., Z.A., and C.C.Z. are listed as inventors on relevant patent applications that were exclusively licensed to Immune-Onc Therapeutics, Inc. by the Board of Regents of the University of Texas System. Authors Z.A., N.Z., and C.C.Z. hold equity in and sponsored Research Agreements with Immune-Onc Therapeutics, Inc. The University of Texas has a financial interest in Immune-Onc in the form of equity and licensing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"368"}}